FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295544> ?p ?o ?g. }

• W4286295544 endingPage "e18019" @default.
• W4286295544 startingPage "e18019" @default.
• W4286295544 abstract "e18019 Background: The standard of care for metastatic or unresectable head and neck squamous cell cancers (HNSCCs) is 5-FU and a platinum doublet with cetuximab or pembrolizumab. However, these regimens are cumbersome as they involve hospitalization for continuous 5-FU infusion and carry a high toxicity profile. In addition, many patients are unfit for this regimen due to poor performance status (PS) or comorbidities. An alternative is paclitaxel, carboplatin, and cetuximab (PCC). PCC has been shown to be a promising induction regimen in small, mostly retrospective studies. Also, low dose chemotherapy may improve tolerability. Our study evaluates the tolerability and efficacy of low dose PCC with or without concurrent palliative radiation therapy (RT) in patients with metastatic or unresectable HNSCCs. Methods: This retrospective observational study included 40 patients with metastatic or unresectable HNSCCs at a single academic center who received PCC between August 2017 and January 2022. Included patients were not candidates for standard frontline therapies due to either PS, comorbidities, prior progression on these therapies, plan for RT, or patient preference. Chart review was performed to grade adverse events (AEs) according to CTCAE criteria. Progression free survival (PFS), overall survival (OS), and response to treatment were assessed per RECIST 1.1 guidelines. Results: Of the 40 patients, mean age was 69.6 years (SD 15.4), and 82.5% were male. Common primary sites were oral (13, 32.5%), oropharynx (12, 30%), hypopharynx (4, 10%), and sinus (4, 10%). Most patients had Stage IVa disease (16, 40%) followed by IVc (12, 30%) and IVb (6, 15%). The remainder (6, 15%) had stage III or unknown stage. Patients received weekly paclitaxel (30-50 mg/m2), carboplatin (AUC 1.5-2), and cetuximab 400 mg/m2 loading followed by 250 mg/m2 maintenance dose. 8 patients (20%) received concurrent RT. Most were treated with palliative intent (32, 80%) and a few induction intent (8, 20%). Prior to PCC, 11 patients had prior salvage surgery, 19 prior RT, and 18 prior systemic therapy. Baseline ECOG PS was 0-2 in 37 patients (92.5%). The most common AEs were skin rash (27, 67.5%), fatigue (22, 55%), and mucositis (12, 30%). 7 patients (17.5%) experienced a grade 3-4 AE, which were mostly hematologic. 2 of the 8 patients on concurrent RT experienced a grade 3-4 AE. 5 patients (12.5%) stopped PCC treatment due to toxicities. 8 patients (20%) had progression on initial follow up imaging. Median duration of response was 4.3 months. PFS was 7.8 months. Median OS was 19.2 months. Conclusions: Our study supports the use of PCC in metastatic or unresectable HNSCCs. This regimen can be considered in patients with suboptimal PS who are not candidates for standard frontline therapies or for those planned for palliative RT. PCC can be used safely and effectively with or without concurrent RT." @default.
• W4286295544 created "2022-07-21" @default.
• W4286295544 creator A5020651485 @default.
• W4286295544 creator A5030166341 @default.
• W4286295544 creator A5056758900 @default.
• W4286295544 date "2022-06-01" @default.
• W4286295544 modified "2023-09-28" @default.
• W4286295544 title "Efficacy and tolerability of a low dose weekly paclitaxel, carboplatin, cetuximab (PCC) regimen for metastatic or unresectable head and neck squamous cell carcinomas." @default.
• W4286295544 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e18019" @default.
• W4286295544 hasPublicationYear "2022" @default.
• W4286295544 type Work @default.
• W4286295544 citedByCount "0" @default.
• W4286295544 crossrefType "journal-article" @default.
• W4286295544 hasAuthorship W4286295544A5020651485 @default.
• W4286295544 hasAuthorship W4286295544A5030166341 @default.
• W4286295544 hasAuthorship W4286295544A5056758900 @default.
• W4286295544 hasConcept C121608353 @default.
• W4286295544 hasConcept C126322002 @default.
• W4286295544 hasConcept C141071460 @default.
• W4286295544 hasConcept C143998085 @default.
• W4286295544 hasConcept C197934379 @default.
• W4286295544 hasConcept C2776530083 @default.
• W4286295544 hasConcept C2776694085 @default.
• W4286295544 hasConcept C2776907518 @default.
• W4286295544 hasConcept C2778239845 @default.
• W4286295544 hasConcept C2778375690 @default.
• W4286295544 hasConcept C2778822529 @default.
• W4286295544 hasConcept C2779984678 @default.
• W4286295544 hasConcept C2779998722 @default.
• W4286295544 hasConcept C2781413609 @default.
• W4286295544 hasConcept C2781451048 @default.
• W4286295544 hasConcept C509974204 @default.
• W4286295544 hasConcept C526805850 @default.
• W4286295544 hasConcept C71924100 @default.
• W4286295544 hasConceptScore W4286295544C121608353 @default.
• W4286295544 hasConceptScore W4286295544C126322002 @default.
• W4286295544 hasConceptScore W4286295544C141071460 @default.
• W4286295544 hasConceptScore W4286295544C143998085 @default.
• W4286295544 hasConceptScore W4286295544C197934379 @default.
• W4286295544 hasConceptScore W4286295544C2776530083 @default.
• W4286295544 hasConceptScore W4286295544C2776694085 @default.
• W4286295544 hasConceptScore W4286295544C2776907518 @default.
• W4286295544 hasConceptScore W4286295544C2778239845 @default.
• W4286295544 hasConceptScore W4286295544C2778375690 @default.
• W4286295544 hasConceptScore W4286295544C2778822529 @default.
• W4286295544 hasConceptScore W4286295544C2779984678 @default.
• W4286295544 hasConceptScore W4286295544C2779998722 @default.
• W4286295544 hasConceptScore W4286295544C2781413609 @default.
• W4286295544 hasConceptScore W4286295544C2781451048 @default.
• W4286295544 hasConceptScore W4286295544C509974204 @default.
• W4286295544 hasConceptScore W4286295544C526805850 @default.
• W4286295544 hasConceptScore W4286295544C71924100 @default.
• W4286295544 hasIssue "16_suppl" @default.
• W4286295544 hasLocation W42862955441 @default.
• W4286295544 hasOpenAccess W4286295544 @default.
• W4286295544 hasPrimaryLocation W42862955441 @default.
• W4286295544 hasRelatedWork W2020319882 @default.
• W4286295544 hasRelatedWork W2022084568 @default.
• W4286295544 hasRelatedWork W2354390866 @default.
• W4286295544 hasRelatedWork W2423163941 @default.
• W4286295544 hasRelatedWork W2956752266 @default.
• W4286295544 hasRelatedWork W3011871240 @default.
• W4286295544 hasRelatedWork W3164367827 @default.
• W4286295544 hasRelatedWork W4286295544 @default.
• W4286295544 hasRelatedWork W4296685310 @default.
• W4286295544 hasRelatedWork W4310754871 @default.
• W4286295544 hasVolume "40" @default.
• W4286295544 isParatext "false" @default.
• W4286295544 isRetracted "false" @default.
• W4286295544 workType "article" @default.